Patterson Companies (PDCO) Stock

Patterson enters into a definitive agreement to be acquired by Patient Square Capital at a valuation of approximately $4.1 billion.

NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Patterson Companies, Inc. (NASDAQ: PDCO ), relating to the proposed merger with Patient Square Capital.

Shareholders will receive $31.35 in cash per share under terms of the deal.

Patterson Approved Vendor status will pave the way for customers to securely use new payments capabilities. VALHALLA, N.Y.

Patterson Companies, Inc. (NASDAQ:PDCO ) Q2 2025 Earnings Conference Call December 5, 2024 8:30 AM ET Company Participants John Wright - Vice President, Investor Relations Don Zurbay - President and Chief Executive Officer Kevin Barry - Chief Financial Officer Conference Call Participants Michael Cherny - Leerink Partners Jeffrey Johnson - Baird Kevin Caliendo - UBS Jonathan Block - Stifel Erin Wright - Morgan Stanley Jason Bednar - Piper Sandler Sameer Patel - Evercore ISI Allen Lutz - Bank of America Steven Valiquette - Mizuho Securities Brandon Vazquez - William Blair Operator Thank you for standing by and welcome to the Patterson Companies' Second Quarter Fiscal 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

While the top- and bottom-line numbers for Patterson Cos. (PDCO) give a sense of how the business performed in the quarter ended October 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Patterson Cos. (PDCO) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.49 per share.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Patterson Cos. (PDCO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended October 2024.

PDCO's fiscal second-quarter results are likely to reveal a decline in both the Dental and Animal Health segments, reflecting challenges like moderating traffic to clinics.